Stichting ReumaNederland

Their core work

ReumaNederland (Dutch Arthritis Foundation) is the Netherlands' leading patient organization and research funder for rheumatic and musculoskeletal diseases. In H2020, they co-fund and support training networks and research projects focused on osteoarthritis, cartilage regeneration, and inflammatory joint diseases. Their role bridges patient advocacy with translational research — they bring clinical relevance, patient perspectives, and co-funding capacity to academic consortia working on regenerative therapies for joints and spine.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2017), ReumaNederland focused on structural repair — cartilage regeneration, bone healing, tissue engineering, and biomaterials through projects like TargetCaRe and CarBon. From 2019 onward, their involvement shifted toward biological and cellular therapies: iPSpine brought stem cell approaches, ArthritisHeal addressed inflammation resolution and personalised treatment, and OSTASKILLS consolidated around translational cell therapy. The trajectory is clear — from engineering replacement tissues to understanding and manipulating the body's own repair mechanisms.

ReumaNederland is moving from materials-based repair toward biological and cell-based regenerative therapies for joint diseases, with growing emphasis on training the next generation of researchers through MSCA programmes.

How they like to work

ReumaNederland primarily participates as a third-party contributor or partner (4 of 5 projects), providing co-funding, patient perspectives, and research coordination support rather than leading the science directly. Their one coordinator role — OSTASKILLS, an MSCA-COFUND training programme — reflects their strength in research funding and training infrastructure. With 58 unique partners across 15 countries, they connect widely across European rheumatology networks, making them a valuable consortium node for access to the Dutch patient and clinical research ecosystem.

ReumaNederland has collaborated with 58 unique partners across 15 countries, indicating a broad European network concentrated in musculoskeletal and regenerative medicine research. Their Amsterdam base and patient foundation status give them strong ties to Dutch university hospitals and clinical research centres.

What sets them apart

ReumaNederland occupies a rare niche as a patient-driven research funder participating directly in EU consortia — they bring co-funding, patient engagement infrastructure, and clinical relevance that pure academic partners cannot. Their coordinator role in OSTASKILLS (EUR 1.08M) demonstrates they can anchor training programmes, not just contribute to them. For consortium builders in musculoskeletal research, they offer both credibility with patient communities and a track record of sustained investment in translational arthritis research.

Highlights from their portfolio

• OSTASKILLS
  Their only coordinator role with EUR 1.08M funding — an MSCA-COFUND training programme for next-generation osteoarthritis researchers, signalling strategic investment in field-building.
• iPSpine
  Their entry into stem cell-based regenerative medicine for spinal disc degeneration, marking a clear expansion beyond traditional joint-focused work.
• ArthritisHeal
  Focused on fundamental mechanisms of inflammation resolution and personalised therapy — represents their push toward precision medicine in arthritis.